EXHIBIT 99.1

                       Press Release dated March 15, 2001



                AGREEMENT WITH PRAXIS PHARMACEUTICALS TERMINATED


March 15, 2001 SEATTLE, WA.,FAIRCHILD INTERNATIONAL (FRCD: OTCBB), announced
today that it has mutually terminated it's licensing agreement with Praxis
Pharmaceuticals Inc. (PRXX:OTCBB) for the development of two over-the-counter
drug applications for wrinkles and arthritis.

Praxis has agreed to pay Fairchild 30% of net revenues from sales of the two
applications in the field of use to a maximum of $250,000 over the first 3 years
of sales. Praxis will be able to retain the Fairchild shares that were issued to
it as partial consideration for the license.

Fairchild has not been able to raise sufficient funding to further the
development efforts with Praxis. Fairchild is presently looking at other
business ventures, particularly in the resource sector where the company will be
able to raise sufficient capital and provide shareholder value.


FOR MORE INFORMATION, CONTACT:

INVESTOR RELATIONS AT 604-669-1040


The Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made on behalf of the Company. All such
forward-looking statements are, by necessity, only estimates of future results
and actual results achieved by Fairchild may differ materially from these
statements due to a number of factors. Fairchild assumes no obligation to update
these forward-looking statements to reflect actual results, changes in
assumptions or changes in other factors affecting such statements. You should
independently investigate and fully understand all risks before making
investment decisions